MOTIVATION: Pathway analyses have led to more insight into the underlying biological functions related to the phenotype of interest in various types of omics data. Pathway-based statistical approaches have been actively developed, but most of them do not consider correlations among pathways. Because it is well known that there are quite a few biomarkers that overlap between pathways, these approaches may provide misleading results. In addition, most pathway-based approaches tend to assume that biomarkers within a pathway have linear associations with the phenotype of interest, even though the relationships are more complex. RESULTS: To model complex effects including non-linear effects, we propose a new approach, Hierarchical structural CoMponent analysis using Kernel (HisCoM-Kernel). The proposed method models non-linear associations between biomarkers and phenotype by extending the kernel machine regression and analyzes entire pathways simultaneously by using the biomarker-pathway hierarchical structure. HisCoM-Kernel is a flexible model that can be applied to various omics data. It was successfully applied to three omics datasets generated by different technologies. Our simulation studies showed that HisCoM-Kernel provided higher statistical power than other existing pathway-based methods in all datasets. The application of HisCoM-Kernel to three types of omics dataset showed its superior performance compared to existing methods in identifying more biologically meaningful pathways, including those reported in previous studies. AVAILABILITY AND IMPLEMENTATION: The HisCoM-Kernel software is freely available at http://statgen.snu.ac.kr/software/HisCom-Kernel/. The RNA-seq data underlying this article are available at https://xena.ucsc.edu/, and the others will be shared on reasonable request to the corresponding author. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

BACKGROUND: Component-based structural equation modeling methods are now widely used in science, business, education, and other fields. This method uses unobservable variables, i.e., "latent" variables, and structural equation model relationships between observable variables. Here, we applied this structural equation modeling method to biologically structured data. To identify candidate drug-response biomarkers, we first used proteomic peptide-level data, as measured by multiple reaction monitoring mass spectrometry (MRM-MS), for liver cancer patients. MRM-MS is a highly sensitive and selective method for proteomic targeted quantitation of peptide abundances in complex biological samples. RESULTS: We developed a component-based drug response prediction model, having the advantage that it first combines collapsed peptide-level data into protein-level information, facilitating subsequent biological interpretation. Our model also uses an alternating least squares algorithm, to efficiently estimate both coefficients of peptides and proteins. This approach also considers correlations between variables, without constraint, by a multiple testing problem. Using estimated peptide and protein coefficients, we selected significant protein biomarkers by permutation testing, resulting in our model for predicting liver cancer response to the tyrosine kinase inhibitor sorafenib. CONCLUSIONS: Using data from a cohort of liver cancer patients, we then "fine-tuned" our model to successfully predict drug responses, as demonstrated by a high area under the curve (AUC) score. Such drug response prediction models may eventually find clinical translation in identifying individual patients likely to respond to specific therapies.

As many diseases are known to be related to microbes, interests in statistical methods for Microbiome-Wide Association Studies (MWAS) are also increasing. In this respect, we systematically investigate the properties of statistical methods for MWAS and compare their performances using simulation data generated from Human Microbiome Project data. We first assessed the type I error rates of eight commonly used methods over different levels of sparsity. Among these, ANCOM and metagenomeSeq methods yielded the well preserved type I error rates regardless of sparsity. In the power comparison study, metagenomeSeq showed higher power than ANCOM. In conclusion, we recommend using metagenomeSeq for the analysis of metagenome data.

High-throughput RNA-seq technology has emerged as a powerful tool for understanding the molecular basis of phenotype variation in biology, including disease. Recently, some correlated RNA-seq datasets started to be generated. While there have been several approaches proposed for identifying the differentially expressed genes (DEGs), not many methods can analyze correlated RNA-seq data. We expect the simultaneous analysis of correlated RNA-seq data to increase of power of detecting DEGs. We propose a multivariate method to find DEGs on correlated RNA-seq data based on the Generalized Estimating Equations (GEE) approach. The advantage of the proposed method is to consider correlated RNA-seq data simultaneously while accounting for correlations. Through real data analysis and simulation studies, we show that our multivariate approach has higher power of detecting DEGs than the existing methods.

MOTIVATION: Recently, many methods have been developed for conducting rare-variant association studies for sequencing data. These methods have primarily been based on gene-level associations but have not been proven to be as effective as expected. Gene-set-level tests have shown great advantages over gene-level tests in terms of power and robustness, because complex diseases are often caused by multiple genes that comprise of biological gene sets. RESULTS: Here, we propose several novel gene-set tests that employ rapid and efficient dimensionality reduction. The performance of these tests was investigated using extensive simulations and application to 1058 whole-exome sequences from a Korean population. We identified some known pathways and novel pathways whose rare or common variants are associated with elevated liver enzymes and replicated the results in an independent cohort. AVAILABILITY AND IMPLEMENTATION: Source R code for our algorithm is freely available at http://statgen.snu.ac.kr/software/QTest CONTACT: [email protected] SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

MOTIVATION: Gene-gene interaction (GGI) is one of the most popular approaches for finding and explaining the missing heritability of common complex traits in genome-wide association studies. The multifactor dimensionality reduction (MDR) method has been widely studied for detecting GGI effects. However, there are several disadvantages of the existing MDR-based approaches, such as the lack of an efficient way of evaluating the significance of multi-locus models and the high computational burden due to intensive permutation. Furthermore, the MDR method does not distinguish marginal effects from pure interaction effects. METHODS: We propose a two-step unified model based MDR approach (UM-MDR), in which, the significance of a multi-locus model, even a high-order model, can be easily obtained through a regression framework with a semi-parametric correction procedure for controlling Type I error rates. In comparison to the conventional permutation approach, the proposed semi-parametric correction procedure avoids heavy computation in order to achieve the significance of a multi-locus model. The proposed UM-MDR approach is flexible in the sense that it is able to incorporate different types of traits and evaluate significances of the existing MDR extensions. RESULTS: The simulation studies and the analysis of a real example are provided to demonstrate the utility of the proposed method. UM-MDR can achieve at least the same power as MDR for most scenarios, and it outperforms MDR especially when there are some single nucleotide polymorphisms that only have marginal effects, which masks the detection of causal epistasis for the existing MDR approaches. CONCLUSIONS: UM-MDR provides a very good supplement of existing MDR method due to its efficiency in achieving significance for every multi-locus model, its power and its flexibility of handling different types of traits. AVAILABILITY AND IMPLEMENTATION: A R package "umMDR" and other source codes are freely available at http://statgen.snu.ac.kr/software/umMDR/ CONTACT: [email protected] SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Since most of the cancer markers that have been reported are obtained directly from cancer tissues, it is difficult to use them for early diagnosis of cancer without surgery. Thus, development of markers that can be detected by blood is crucial for making early diagnosis of cancer easier. One of the most feasible types of markers that can be detected by blood is a protein marker. Here, we focus on building prediction methods using the protein markers for early diagnosis of cancer. To develop a prediction model with high prediction ability, it is critical to choose appropriate markers first. Here, we consider a stepwise selection method using area under the receiver operating characteristic curve (Step-AUC) in order to construct a multi-protein prediction model. We showed that the performance of Step-AUC highly depends on the tuning parameter. We compared our proposed Step-AUC method to stepwise selection using information criteria and support vector machine recursive feature extraction (SVM-RFE). We observed that Step-AUC and stepwise selection using Bayesian information criteria (Step-BIC) perform better than other methods. The importance of each marker can be chosen using a new stepwise selection consistency (SSC) measure. The final models include the markers with high SSC measures. We applied our stepwise procedure to pancreatic cancer data and found two markers of interest.

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, which has dismal prognosis because of its silent early symptoms, high metastatic potential, and resistance to conventional therapies. Although a PDAC patient who is diagnosed at an early stage would have a substantial increase in chance of survival, the survival rate is poor because there is no efficient non-invasive diagnostic test in the early stage. In this study, we developed an efficient prediction models to detect PDAC in its early stages. Our prediction models use both mRNA and miRNA expression data from 104 PDAC tissues and 17 normal pancreatic tissues using microarray technology. After quality control, we built prediction models based on support vector machine (SVM) from mRNA and miRNA expressions for detecting early PDAC. To prevent over-fitting effect, we conducted leave-one-out cross validation (LOOCV) and 5-fold cross validation (CV). For independent validation of prediction models, we performed evaluation on independent datasets from Gene Expression Omnibus (GEO). After the validation, we identified 28 single markers and 231 combinations of markers with powerful prediction performance. In addition, the marker candidates are annotated with cancer pathways using gene ontology analysis. Our prediction models for PDAC may have potential for early diagnosis of PDAC.

MOTIVATION: For the past few decades, many statistical methods in genome-wide association studies (GWAS) have been developed to identify SNP-SNP interactions for case-control studies. However, there has been less work for prospective cohort studies, involving the survival time. Recently, Gui et al. (2011) proposed a novel method, called Surv-MDR, for detecting gene-gene interactions associated with survival time. Surv-MDR is an extension of the multifactor dimensionality reduction (MDR) method to the survival phenotype by using the log-rank test for defining a binary attribute. However, the Surv-MDR method has some drawbacks in the sense that it needs more intensive computations and does not allow for a covariate adjustment. In this article, we propose a new approach, called Cox-MDR, which is an extension of the generalized multifactor dimensionality reduction (GMDR) to the survival phenotype by using a martingale residual as a score to classify multi-level genotypes as high- and low-risk groups. The advantages of Cox-MDR over Surv-MDR are to allow for the effects of discrete and quantitative covariates in the frame of Cox regression model and to require less computation than Surv-MDR. RESULTS: Through simulation studies, we compared the power of Cox-MDR with those of Surv-MDR and Cox regression model for various heritability and minor allele frequency combinations without and with adjusting for covariate. We found that Cox-MDR and Cox regression model perform better than Surv-MDR for low minor allele frequency of 0.2, but Surv-MDR has high power for minor allele frequency of 0.4. However, when the effect of covariate is adjusted for, Cox-MDR and Cox regression model perform much better than Surv-MDR. We also compared the performance of Cox-MDR and Surv-MDR for a real data of leukemia patients to detect the gene-gene interactions with the survival time. CONTACT: [email protected]; [email protected].

BACKGROUND: Many gene-set analysis methods have been previously proposed and compared through simulation studies and analysis of real datasets for binary phenotypes. We focused on the survival phenotype and compared the performances of Gene Set Enrichment Analysis (GSEA), Global Test (GT), Wald-type Test (WT) and Global Boost Test (GBST) methods in a simulation study and on two ovarian cancer data sets. We considered two versions of GSEA by allowing different weights: GSEA1 uses equal weights, yielding results similar to the Kolmogorov-Smirnov test; while GSEA2's weights are based on the correlation between genes and the phenotype. RESULTS: We compared GSEA1, GSEA2, GT, WT and GBST in a simulation study with various settings for the correlation structure of the genes and the association parameter between the survival outcome and the genes. Simulation results indicated that GT, WT and GBST consistently have higher power than GSEA1 and GSEA2 across all scenarios. However, the power of the five tests depends on the combination of correlation structure and association parameter. For the ovarian cancer data set, using the FDR threshold of q < 0.1, the GT, WT and GBST detected 12, 6 and 8 significant pathways, respectively, whereas neither GSEA1 nor GSEA2 detected any significant pathways. In addition, among the pathways found significant by GT, WT, and GBST, three pathways--Purine metabolism, Leukocyte transendothelial migration and Jak-STAT signaling pathway--overlapped with those reported in previous ovarian cancer microarray studies. CONCLUSION: Simulation studies and a real data example indicate that GT, WT and GBST tend to have high power, whereas GSEA1 and GSEA2 have lower power. We also found that the power of the five tests is much higher when genes are correlated than when genes are independent, when survival is positively associated with genes. It seems that there is a synergistic effect in detecting significant gene sets when significant genes have within-class correlation and the association between survival and genes is positive or negative (i.e., one-direction correlation).